Clinical trial
Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease
NCT00206661 · Genzyme, a Sanofi Company, Industry · Terminated
Key facts
| NCT number | NCT00206661 |
|---|---|
| Title | Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease |
| Official title | Phase 1/2 Safety, Pharmacokinetic, and Pharmacodynamic Study of Sargramostim (Leukine®) in Pediatric Patients With Active Crohn's Disease, With One-year Surveillance and Retreatment Extension |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Crohn Disease |
| Intervention type | Drug |
| Interventions | Sargramostim (Leukine) |
| Enrollment | 22 |
| Start date | Dec 1, 2004 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: